Treatment News : AbbVie’s '3D' Regimen Shows Promise in Those With Hep C & HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 28, 2014

AbbVie’s '3D' Regimen Shows Promise in Those With Hep C & HIV

AIDS 2014AbbVie’s “3D” regimen has shown high cure rates in treating genotype 1 of hepatitis C virus (HCV) among those coinfected with HIV, both with and without cirrhosis, aidsmap reports. Interim findings from the randomized, open-label TURQUOISE-I study of 12 or 24 weeks of the regimen were presented at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

A total of 63 HIV-positive participants who had genotype 1 of hep C were evenly divided to receive the 3D regimen for 12 or 24 weeks. The 3D regimen consists of the fixed-dose combination of the protease inhibitor ABT-450 and ritonavir co-formulated with the NS5A inhibitor ombitasvir (ABT-267), as well the non-nucleoside polymerase inhibitor dasabuvir (ABT-333), either with or without ribavirin (in this case ribavirin was used).

Ninety-four percent of those in the 12-week group achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Not all of those in the 24-week arm have yet made it 12 weeks past finishing therapy. Ninety-seven percent of them achieved an SVR4, which is a strong predictor of an ultimate cure. Out of 20 participants in this arm who did pass the 12-week mark post-therapy, 95 percent of them had achieved an SVR12.

All the participants had a suppressed HIV viral load and were taking an antiretroviral regimen including Reyataz (atazanavir) or Isentress (raltegravir). Safety testing before the study had shown that there are no adverse drug-drug interactions between those drugs or Truvada (tenofovir/emtricitabine) and the 3D regimen. The ritonavir in the hep C regimen does act as a booster for Reyataz.

The 3D regimen proved generally safe and well tolerated. There were no serious side effects or discontinuations as a result of side effects. The most common included fatigue, insomnia, nausea and headache, most of which were mild or moderate.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: 3D, AbbVie, hepatitis C, HIV, coinfection, TURQUOISE-I, 20th International AIDS Conference, AIDS 2014, ombitasvir, dasabuvir, ABT-267, ABT-333, Reyataz, atazanavir, Isentress, raltegravir, Truvada, tenofovir, emtricitabine, aidsmap.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.